SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313895946> ?p ?o ?g. }

Showing items 1 to 76 of 76 with 100 items per page.

W2313895946 endingPage "949" @default.
W2313895946 startingPage "948.3" @default.
W2313895946 abstract "<h3>Objectives</h3> To analyze the Slovakian experiences in a national multicenter open label non-interventional phase IV study which evaluated tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) and an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor inhibitors (TNFs). <h3>Methods</h3> A prospective open label, single arm study with descriptive statistics used to analyze primary endpoint DAS28 and secondary endpoints: physical disability (HAQ) and safety. Adult patients with moderate to severe active RA who are on infusions therapy of TCZ (8mg/kg) every 4 weeks, after inadequate clinical response to a stable dose of DMARDs. Study has been approved by local ethical committees and all patients provided informed consent before enrollment. TCZ can be given with methotrexate (MTX), or as monotherapy in case of intolerance to MTX or when treatment with MTX was inappropriate. <h3>Results</h3> In 62 RA patients reached one year retention rate 89%. 7 patients were prematurely withdrawn: one of them because of ineffectiveness, 4 adverse events and 2 other reason (withdrawal of inform consent or loss of control). After one year 63% of enrolled patients were in remission (DAS28<2,6) and other 19% reached low activity of disease (DAS28≤3,2). DAS28 index value decreased from baseline rate 6.54±0.78 to 2.99±1.26 (12 week), 2.82±1.21 (24 week), 2.29±1.04 (36 week) and 2.26±1.12 (48 week). After 12 months of TCZ treatment HAQ disability index decreased from average value 1,63±0,61 to 1,21±0,71, while improvment of the minimal clinically important difference (≥0,22) was recorded in 63% of patients. There were no new safety signals compared with other clinical studies. Adverse events have been confirmed in 28 patients, in 25 with low and moderate intensity. Serious adverse events occurred in 3 patients (1 arterial thrombosis, 1 acute sciatica with lumbar stenosis, 1 labile blood pressure). No case of death has been reported. <h3>Conclusions</h3> TCZ in Slovakian RA patients in open label study demonstrated high degree of one year retention rate (89%) with remission in 63% and low activity of disease in other 19% patient, without new safety signals. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1516" @default.
W2313895946 created "2016-06-24" @default.
W2313895946 creator A5002170070 @default.
W2313895946 creator A5025711375 @default.
W2313895946 creator A5038780127 @default.
W2313895946 creator A5038781898 @default.
W2313895946 creator A5066306496 @default.
W2313895946 creator A5091253559 @default.
W2313895946 date "2014-06-01" @default.
W2313895946 modified "2023-10-16" @default.
W2313895946 title "AB0428 Study on the Efficacy and Safety of Tocilizumab in Patients with Rheumatoid Arthritis in Slovakia: One Year Results of Prospective, Open Label Study Close to Clinical Practice" @default.
W2313895946 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1516" @default.
W2313895946 hasPublicationYear "2014" @default.
W2313895946 type Work @default.
W2313895946 sameAs 2313895946 @default.
W2313895946 citedByCount "0" @default.
W2313895946 crossrefType "journal-article" @default.
W2313895946 hasAuthorship W2313895946A5002170070 @default.
W2313895946 hasAuthorship W2313895946A5025711375 @default.
W2313895946 hasAuthorship W2313895946A5038780127 @default.
W2313895946 hasAuthorship W2313895946A5038781898 @default.
W2313895946 hasAuthorship W2313895946A5066306496 @default.
W2313895946 hasAuthorship W2313895946A5091253559 @default.
W2313895946 hasConcept C126322002 @default.
W2313895946 hasConcept C141071460 @default.
W2313895946 hasConcept C142724271 @default.
W2313895946 hasConcept C1862650 @default.
W2313895946 hasConcept C188816634 @default.
W2313895946 hasConcept C197934379 @default.
W2313895946 hasConcept C198451711 @default.
W2313895946 hasConcept C203092338 @default.
W2313895946 hasConcept C204787440 @default.
W2313895946 hasConcept C2777178219 @default.
W2313895946 hasConcept C2777575956 @default.
W2313895946 hasConcept C2781059491 @default.
W2313895946 hasConcept C3019800554 @default.
W2313895946 hasConcept C535046627 @default.
W2313895946 hasConcept C68122502 @default.
W2313895946 hasConcept C71924100 @default.
W2313895946 hasConceptScore W2313895946C126322002 @default.
W2313895946 hasConceptScore W2313895946C141071460 @default.
W2313895946 hasConceptScore W2313895946C142724271 @default.
W2313895946 hasConceptScore W2313895946C1862650 @default.
W2313895946 hasConceptScore W2313895946C188816634 @default.
W2313895946 hasConceptScore W2313895946C197934379 @default.
W2313895946 hasConceptScore W2313895946C198451711 @default.
W2313895946 hasConceptScore W2313895946C203092338 @default.
W2313895946 hasConceptScore W2313895946C204787440 @default.
W2313895946 hasConceptScore W2313895946C2777178219 @default.
W2313895946 hasConceptScore W2313895946C2777575956 @default.
W2313895946 hasConceptScore W2313895946C2781059491 @default.
W2313895946 hasConceptScore W2313895946C3019800554 @default.
W2313895946 hasConceptScore W2313895946C535046627 @default.
W2313895946 hasConceptScore W2313895946C68122502 @default.
W2313895946 hasConceptScore W2313895946C71924100 @default.
W2313895946 hasIssue "Suppl 2" @default.
W2313895946 hasLocation W23138959461 @default.
W2313895946 hasOpenAccess W2313895946 @default.
W2313895946 hasPrimaryLocation W23138959461 @default.
W2313895946 hasRelatedWork W1987294331 @default.
W2313895946 hasRelatedWork W2098703756 @default.
W2313895946 hasRelatedWork W2521758237 @default.
W2313895946 hasRelatedWork W2736593664 @default.
W2313895946 hasRelatedWork W2766107824 @default.
W2313895946 hasRelatedWork W2783466784 @default.
W2313895946 hasRelatedWork W2980857560 @default.
W2313895946 hasRelatedWork W2996380604 @default.
W2313895946 hasRelatedWork W4239841759 @default.
W2313895946 hasRelatedWork W4317651631 @default.
W2313895946 hasVolume "73" @default.
W2313895946 isParatext "false" @default.
W2313895946 isRetracted "false" @default.
W2313895946 magId "2313895946" @default.
W2313895946 workType "article" @default.